Molecular dynamics studies on Mdm2 complexes: An analysis of the inhibitor influence

Biochemical and Biophysical Research Communications

Volumn 424, Issue 2, 2012, Pages 341-347

  Almerico, Anna Maria ^a   Tutone, Marco ^a   Pantano, Licia ^a   Lauria, Antonino ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Benzodiazepine; Mdm2; Molecular dynamics; Nutlin; P53

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; NUTLIN 2; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BETA SHEET; COMPLEX FORMATION; LIGAND BINDING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; SIMULATION; X RAY CRYSTALLOGRAPHY;

BENZODIAZEPINES; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84864302957     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.138     Document Type: Article

References (27)

1. Kastan M.B., Onyekwere O., Sidransky D., et al. Participation of p53 pProtein in the cellular response to DNA damage. Cancer Res. 1991, 51:6304-6311.
2. Wu X., Levine A.J. P53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 1994, 91:3602-3606.
3. Hermeking H., Eick D. Mediation of c-myc induced apoptosis by p53. Science 1994, 265:2091-2093.
4. Oliner J.D., Pietenpol J.A., Vogelstein B., et al. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993, 362:857-860.
5. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
6. Oliner J.D., Kinzler K.W., Vogelstein B., et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83.
7. Bueso-Ramos C.E., Yang Y., Albitar M., et al. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993, 82:2617-2623.
8. Wasylyk C., Salvi R., Wasylyk B., et al. P53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999, 18:1921-1934.
9. Bottger A., Bottger V., Lane D.P., et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 1997, 269:744-756.
10. Garcia-Echeverria C., Chene P., Blommers M.J., Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 2000, 43:3205-3208.
11. Lyubomir T.V. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13:23-31.
12. Massova I., Kollman P.A. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J. Am. Chem. Soc. 1999, 121:8133-8143.
13. Zhong H., Carlson H.A. Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 2005, 58:222-234.
14. Espinoza-Fonseca L.M., Trujillo-Ferrara J.G. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 2006, 83:365-373.
15. Macchiarulo A., Giacchè N., Carotti A., et al. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J. Chem. Inf. Model. 2008, 48:1999-2009.
16. Showalter S.A., Bruschweiler-Li L., Bruschweiler R., et al. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 2008, 130:6472-6478.
17. Joseph T.L., Madhumalar A., Verma C., et al. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle 2010, 9:1167-1181.
18. Yu G.W., Vaysburd M., Fersht A.R., et al. Structure of human MDM4 N-terminal domain bound to a single-domain antibody. J. Mol. Biol. 2009, 385:1578-1589.
19. Dastidar S.G., Madhumalar A., Verma C.S., et al. Forces mediating protein-protein interactions: a computational study of p53 " approaching" MDM2. Theor. Chem. Acc. 2010, 125:621-635.
20. Berendsen H.J.C., Van der Spoel D., Van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comp. Phys. Comm. 1995, 91:43-56.
21. E. Lindahl, B. Hess, D. Van der Spoel, GROMACS 3.0: a package for molecular simulation and trajectory analysis, J. Mol. Mod. 7 (2001) 306-317.
22. Pedretti A., Villa L., Vistoli G. VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. J. Mol. Graph. Model. 2002, 21:47-49.
23. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. Model 1996, 14:33-38.
24. Schrödinger Suite 2008 Induced Fit Docking protocol; Glide version 5.0, Schrödinger, LLC, New York, NY, 2005; Prime version 1.7, Schrödinger, LLC, New York, NY, 2005.
25. Fry D.C., Emerson S.D., Podlaski F., et al. NMR structure of a complex between MDM2 and a small molecule inhibitor. J. Biomol. NMR 2004, 30:163-173.
26. Schon O., Friedler A., Freund S., Fersht A.R. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. 2004, 336:197-202.
27. Carotti A., Macchiarulo A., Giacchè N., Pellicciari R. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition. Proteins 2009, 77:524-535.